Literature DB >> 18600385

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Jing-Ting Li1, Zhang-Xiu Liao, Jie Ping, Dan Xu, Hui Wang.   

Abstract

Activation of hepatic stellate cells (HSCs) is the dominant event in liver fibrosis. The early events in the organization of HSC activation have been termed initiation. Initiation encompasses rapid changes in gene expression and phenotype that render the cells responsive to cytokines and other local stimuli. Cellular responses following initiation are termed perpetuation, which encompasses those cellular events that amplify the activated phenotype through enhanced growth factor expression and responsiveness. Multiple cells and cytokines play a part in the regulation of HSC activation. HSC activation consists of discrete phenotype responses, mainly proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis and retinoid loss. Currently, antifibrotic therapeutic strategies include inhibition of HSC proliferation or stimulation of HSC apoptosis, downregulation of collagen production or promotion of its degradation, administration of cytokines, and infusion of mesenchymal stem cells. In this review, we summarize the latest advances in our understanding of the mechanisms of HSC activation and possible antifibrotic therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18600385     DOI: 10.1007/s00535-008-2180-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  87 in total

1.  Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Authors:  Goutham Narla; Analisa DiFeo; Shen Yao; Asoka Banno; Eldad Hod; Helen L Reeves; Rui F Qiao; Olga Camacho-Vanegas; Alice Levine; Alexander Kirschenbaum; Andrew M Chan; Scott L Friedman; John A Martignetti
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

2.  Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis.

Authors:  K Hironaka; I Sakaida; Y Matsumura; S Kaino; K Miyamoto; K Okita
Journal:  Biochem Biophys Res Commun       Date:  2000-01-07       Impact factor: 3.575

3.  The DNA binding protein BTEB mediates acetaldehyde-induced, jun N-terminal kinase-dependent alphaI(I) collagen gene expression in rat hepatic stellate cells.

Authors:  A Chen; B H Davis
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

4.  Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.

Authors:  M Okuno; K Akita; H Moriwaki; N Kawada; K Ikeda; K Kaneda; Y Suzuki; S Kojima
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

5.  Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.

Authors:  Miriam Bueno; Silvia Salgado; Carlos Beas-Zárate; Juan Armendariz-Borunda
Journal:  J Gene Med       Date:  2006-11       Impact factor: 4.565

6.  The bone marrow functionally contributes to liver fibrosis.

Authors:  Francesco P Russo; Malcolm R Alison; Brian W Bigger; Eunice Amofah; Aikaterini Florou; Farhana Amin; George Bou-Gharios; Rosemary Jeffery; John P Iredale; Stuart J Forbes
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

7.  SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells.

Authors:  Shigeki Tsukada; John K Westwick; Kenichi Ikejima; Nobuhiro Sato; Richard A Rippe
Journal:  J Biol Chem       Date:  2005-01-12       Impact factor: 5.157

8.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

9.  Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis.

Authors:  M Matsuoka; H Tsukamoto
Journal:  Hepatology       Date:  1990-04       Impact factor: 17.425

10.  Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing.

Authors:  R Shao; W Yan; D C Rockey
Journal:  J Biol Chem       Date:  1999-01-29       Impact factor: 5.157

View more
  69 in total

1.  Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.

Authors:  Leila Gobejishvili; Shirish Barve; Katja Breitkopf-Heinlein; Yan Li; JingWen Zhang; Diana V Avila; Steven Dooley; Craig J McClain
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

2.  The Role of Signal Transducer and Activator of Transcription 5 and Transforming Growth Factor-β1 in Hepatic Fibrosis Induced by Chronic Hepatitis C Virus Infection in Egyptian Patients.

Authors:  Mona A Abu El Makarem; Ghada M El-Sagheer; Moustafa A Abu El-Ella
Journal:  Med Princ Pract       Date:  2018-01-31       Impact factor: 1.927

3.  miRNA studies in in vitro and in vivo activated hepatic stellate cells.

Authors:  Gunter Maubach; Michelle Chin Chia Lim; Jinmiao Chen; Henry Yang; Lang Zhuo
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 4.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 5.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

6.  CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease.

Authors:  Denitra A Breuer; Maria Cristina Pacheco; M Kay Washington; Stephanie A Montgomery; Alyssa H Hasty; Arion J Kennedy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

7.  Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt.

Authors:  Gang Deng; Xiang-Jun Huang; Hong-Wu Luo; Fei-Zhou Huang; Xun-Yang Liu; Yong-Heng Wang
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

Review 8.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

Review 9.  Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Nanotechnology applications for the therapy of liver fibrosis.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Maria Luisa Bondì; Giuseppe Montalto; Melchiorre Cervello
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.